Diane Smith
Medical · Carrolltown, PANPI 1962663609
Payments from drug & device makers
Across 94 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$204
- AstraZeneca$199
- Abbott$193
- Exact Sciences$177
- Novo Nordisk$171
- Johnson & Johnson$146
- plus $704 from 12 others
What the payments were for
- Speaking & faculty fees$1368%
- Food & beverage$1,65792%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 12 | $204 |
| AstraZeneca | 13 | $199 |
| Abbott | 11 | $193 |
| Exact Sciences | 8 | $177 |
| Novo Nordisk | 9 | $171 |
| Johnson & Johnson | 9 | $146 |
| Pfizer | 8 | $137 |
| EPI Health, LLC | 1 | $136 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $95 |
| Merck | 5 | $94 |
| E.r. Squibb & Sons, L.L.C. | 4 | $69 |
| Dexcom, Inc. | 2 | $31 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Lilly USA, LLC | 2 | $29 |
| Boston Scientific | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| GSK | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WYNZORA$136
How this compares
$1,793 in reported general payments places this provider in the 75th percentile of 2,594 medical providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 18 | $17,345 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $13,899 |
| JanuviaSitagliptin Phosphate | 13 | $6,893 |
| InvokanaCanagliflozin | 12 | $5,606 |
| Atorvastatin Calcium | 129 | $2,250 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,891 |
| Pantoprazole Sodium | 138 | $1,791 |
| Lisinopril | 145 | $1,369 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $1,021 |
| Losartan Potassium | 64 | $1,004 |
| Sertraline Hcl | 72 | $920 |
| Rosuvastatin Calcium | 36 | $856 |
| Glipizide ErGlipizide | 35 | $839 |
| Amlodipine Besylate | 115 | $776 |
| Levothyroxine Sodium | 44 | $703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $204 | $17,34518 claims |
| GSKTrelegy Ellipta | $11 | $13,89923 claims |
| MerckJanuvia | $94 | $6,89313 claims |
| Johnson & JohnsonInvokana | $146 | $5,60612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Carrolltown
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.